BR112020005875A2 - liberação de composições farmacêuticas que incluem intensificadores da permeação - Google Patents

liberação de composições farmacêuticas que incluem intensificadores da permeação Download PDF

Info

Publication number
BR112020005875A2
BR112020005875A2 BR112020005875-0A BR112020005875A BR112020005875A2 BR 112020005875 A2 BR112020005875 A2 BR 112020005875A2 BR 112020005875 A BR112020005875 A BR 112020005875A BR 112020005875 A2 BR112020005875 A2 BR 112020005875A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
composition according
fact
less
minutes
Prior art date
Application number
BR112020005875-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Stephen Paul Wargacki
Rajesh Kumar Kainthan
Alexander Mark Schobel
Original Assignee
Aquestive Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aquestive Therapeutics, Inc. filed Critical Aquestive Therapeutics, Inc.
Publication of BR112020005875A2 publication Critical patent/BR112020005875A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7007—Drug-containing films, membranes or sheets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186—Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112020005875-0A 2017-09-26 2018-09-26 liberação de composições farmacêuticas que incluem intensificadores da permeação BR112020005875A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762563534P 2017-09-26 2017-09-26
US62/563,534 2017-09-26
PCT/US2018/052927 WO2019067596A1 (en) 2017-09-26 2018-09-26 ADMINISTRATIVE PHARMACEUTICAL COMPOSITIONS CONTAINING PERMEATION PROMOTERS

Publications (1)

Publication Number Publication Date
BR112020005875A2 true BR112020005875A2 (pt) 2020-09-29

Family

ID=63858155

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020005875-0A BR112020005875A2 (pt) 2017-09-26 2018-09-26 liberação de composições farmacêuticas que incluem intensificadores da permeação

Country Status (9)

Country Link
US (1) US20190091281A1 (enExample)
EP (1) EP3687508A1 (enExample)
JP (2) JP2020535232A (enExample)
KR (1) KR20200059269A (enExample)
CN (1) CN111148512A (enExample)
BR (1) BR112020005875A2 (enExample)
CA (1) CA3076751A1 (enExample)
IL (2) IL311142A (enExample)
WO (1) WO2019067596A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111465391A (zh) * 2017-09-27 2020-07-28 阿奎斯蒂弗医疗股份有限公司 具有增强的递送的肾上腺素和前药的组合物
CA3105187A1 (en) 2018-06-28 2020-01-02 Arx, Llc Dispensing method for producing dissolvable unit dose film constructs
US12440472B2 (en) * 2021-06-16 2025-10-14 Intelgenx Corp. Stable tryptamine oral films

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2193891B (en) * 1986-08-18 1990-07-25 Sandoz Ltd Nasal pharmaceutical composition containing a somatostatin anologue.
GB8620035D0 (en) * 1986-08-18 1986-10-01 Sandoz Ltd Organic compounds
US5879690A (en) * 1995-09-07 1999-03-09 Perricone; Nicholas V. Topical administration of catecholamines and related compounds to subcutaneous muscle tissue using percutaneous penetration enhancers
US20030124176A1 (en) * 1999-12-16 2003-07-03 Tsung-Min Hsu Transdermal and topical administration of drugs using basic permeation enhancers
US7666337B2 (en) 2002-04-11 2010-02-23 Monosol Rx, Llc Polyethylene oxide-based films and drug delivery systems made therefrom
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US7425292B2 (en) 2001-10-12 2008-09-16 Monosol Rx, Llc Thin film with non-self-aggregating uniform heterogeneity and drug delivery systems made therefrom
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
SE0302924D0 (sv) * 2003-11-05 2003-11-05 Camurus Ab Pharmaceutical composition having a cationic excipient
US20110257096A1 (en) * 2004-08-25 2011-10-20 Aegis Therapeutics, Inc. Compositions for drug administration
US20060073173A1 (en) * 2004-10-04 2006-04-06 Maria Banach Large-scale manufacturing process for the production of pharmaceutical compositions
KR20130114229A (ko) * 2005-06-03 2013-10-16 애크럭스 디디에스 피티와이 리미티드 경피 약물 전달 방법 및 조성물
CA3044884A1 (en) 2009-12-07 2011-06-16 Arbutus Biopharma Corporation Compositions for nucleic acid delivery
WO2011116139A2 (en) * 2010-03-16 2011-09-22 Chiasma Inc. Improved pharmaceutical compositions and methods of delivery
IE20100174A1 (en) * 2010-03-25 2012-02-29 Trinity College Dublin Transdermal administration of peptides
JP5912126B2 (ja) * 2010-11-26 2016-04-27 ユニバーシティ・オブ・ジ・ウィトウォーターズランド・ヨハネスブルクＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｔｈｅ Ｗｉｔｗａｔｅｒｓｒａｎｄ， Ｊｏｈａｎｎｅｓｂｕｒｇ 医薬投与形態
HK1208812A1 (en) * 2012-07-06 2016-03-18 Leo Pharma A/S A topical composition comprising a film-forming polymer for delivering an active ingredient to skin
FR3013589B1 (fr) * 2013-11-28 2017-03-31 Soc D'exploitation De Produits Pour Les Ind Chimiques Seppic Composition d'alkyl polyglucosides et d'acides gras cationisees
WO2017072774A1 (en) * 2015-10-29 2017-05-04 Solubest Ltd Pharmaceutical compositions for transmucosal delivery

Also Published As

Publication number Publication date
KR20200059269A (ko) 2020-05-28
JP2024156672A (ja) 2024-11-06
EP3687508A1 (en) 2020-08-05
US20190091281A1 (en) 2019-03-28
CN111148512A (zh) 2020-05-12
IL273477B2 (en) 2024-08-01
IL273477A (en) 2020-05-31
IL273477B1 (en) 2024-04-01
IL311142A (en) 2024-04-01
CA3076751A1 (en) 2019-04-04
JP2020535232A (ja) 2020-12-03
WO2019067596A1 (en) 2019-04-04

Similar Documents

Publication Publication Date Title
JP7653218B2 (ja) 送達増強エピネフリン組成物
JP7431724B2 (ja) 増強された透過を有する医薬組成物
KR102536696B1 (ko) 향상된 투과성을 가지는 약물학적 조성물
JP2026027254A (ja) 増強された送達のエピネフリン及びプロドラッグ組成物
JP2024156672A (ja) 透過エンハンサーを含む送達医薬組成物
CN121889146A (zh) 增强肾上腺素的递送和前药组合物
US12427121B2 (en) Enhanced delivery epinephrine compositions
JP2024540936A (ja) 増大された安定性プロファイルを有する医薬組成物
WO2023245069A2 (en) Enhanced delivery epinephrine and prodrug compositions
US20250281392A1 (en) Topical delivery of epinephrine and prodrug compositions
US20260108422A1 (en) Pharmaceutical film storage and dispenser device
WO2026024790A1 (en) Methods of administering enhanced delivery epinephrine and prodrug compositions
WO2026090387A1 (en) Methods of administering enhanced delivery epinephrine and prodrug compositions to treat allergy
BR112018072539B1 (pt) Composições de epinefrina de administração aumentada

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]